Case study on API residual analysis

July 29, 2011

Results from research conducted by scientists at Pfizer for a new method for residual active pharmaceutical ingredient (API) analysis have recently been published in a case study by Phenomenex.

Results from research conducted by scientists at Pfizer for a new method for residual active pharmaceutical ingredient (API) analysis have recently been published in a case study by Phenomenex. The new method replaces 16 individual analyses and has reportedly provided cost savings of £320,000 (more than $516,000) per year. The method requires just one UHPLC instrument using Phenomenex’s Kinetex 1.7 micron core-shell columns to resolve all 16 ingredients in 6 minutes. It uses less solvent, reduces waste disposal costs and frees up laboratory time.

"High-volume laboratories, such as those in pharmaceutical QC, have an acute need to reduce operating costs and free up resources," explains Jeremy Bierman, brand manager for HPLC products. "The Kinetex core-shell technology allows the development of faster and more efficient analytical methods to deliver significant cost and time savings."The method can be reviewed and/or downloaded atwww.phenomenex.com/info/form/casestudy

Related Content:

News | UHPLC